Abstract
Mitochondrial copy number is known to vary among humans and across tissues, and a population-based study of mitochondrial genome copy number (MT-CN) in blood – as estimated from genome sequencing data – observed strong (∼54%) heritability. However, the genetic causes and phenotypic consequences of MT-CN variation in humans are not well-studied. Here, we studied MT-CN variation in blood-derived DNA from 19,184 Finnish individuals with deep cardiometabolic trait measurements using a combination of whole genome (N = 4,163) and exome sequencing (N = 19,034) data as well as imputed array genotypes (N = 17,718). We confirmed that MT-CN in blood is highly heritable (31% by GREML). We identified two loci in the nuclear genome that are significantly associated with MT-CN variation: a common variant at the MYB-HBS1L locus (P = 1.6×10−8), which has previously been associated with numerous hematological parameters; and a burden of rare variants in the TMB1M1 gene (P = 3.0×10−8), which has been reported to protect against non-alcoholic fatty liver disease in model organisms. We also found that MT-CN is strongly associated with insulin levels (P = 2.0×10−21), fat mass (P = 4.5×10−16), and other related traits. Using a Mendelian randomization framework, we constructed a genetic instrument for MT-CN using penalized regression with adjustment for potentially confounding covariates and found a significant association with insulin levels, which suggests that our MT-CN measurement in blood may be causally related to metabolic syndrome. Finally, we computed our genetic instrument in UK Biobank participants and tested it against a set of cell count and cardiometabolic traits. We found significant associations between MT-CN and both neutrophil and platelet counts (P = 1.8×10−8 and P = 1.2×10−3). While the association between MT-CN and metabolic syndrome traits was replicated in the UK Biobank, adjusting for cell counts largely eliminated these signals, suggesting that MT-CN is actually a proxy measurement for neutrophil and platelet counts in its effect on metabolic syndrome. Taken together, these results suggest that measurements of MT-CN in blood-derived DNA may primarily reflect differences in cell-type composition, and that these differences may be causally linked to insulin and related traits.
Author summary The number of mitochondria per cell is variable between tissues and between individuals, and prior studies have shown that mitochondrial genome copy number in blood (MT-CN) – as estimated indirectly from sequencing of blood-derived DNA – is a genetically determined trait that varies among humans. We studied genetic data from approximately 19,000 Finnish individuals and showed that MT-CN is significantly associated with insulin and related metabolic traits, providing evidence that MT-CN levels play a role in determining these traits. Consistent with a previous study, we showed that genetics play a significant role in determining blood-derived MT-CN. We also found new evidence linking several regions of the genome to MT-CN, including a gene known to be associated with non-alcoholic fatty liver disease. Finally, we found that in the link between blood-derived MT-CN and metabolic syndrome, MT-CN likely represents the relative quantities of circulating immune cells, providing further evidence for the role of inflammation in metabolic syndrome.
Competing Interest Statement
NOS has received grant funding from Regeneron Pharmaceuticals for unrelated work.
Funding Statement
This work was funded by the NHGRI (https://www.genome.gov) Centers for Common Disease Genetics (grant number UM1 HG008853 to IMH and NOS), the NHGRI largescale sequencing grant (grant number 5U54HG003079), the Sigrid Jusélius Foundation (to SR), the University of Helsinki HiLIFE Fellow grants 2017-2020 (to SR), the Academy of Finland Center of Excellence in Complex Disease Genetics (grant number 312062 to SR), the Academy of Finland (grant number 285380 to SR), the National Heart, Lung and Blood Institute (grant number T32HL007081 to EY), and the National Center for Advancing Translational Sciences (grant number UL1TR002345 to EY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants in both the METSIM and FINRISK studies provided informed consent, and study protocols were approved by the Ethics Committees at participating institutions (National Public Health Institute of Finland; Hospital District of Helsinki and Uusimaa; Hospital District of Northern Savo). All relevant ethics committees approved this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
METSIM WGS, METSIM WES, and FINRISK WES sequence data are available through dbGaP (accessions phs001579, phs000752, and phs000756). METSIM variant data as well as MT-CN phenotype values will soon be available through AnVIL (accessions TBD). Imputed array GWAS summary statistics from METSIM and WES SKAT-O summary statistics from the joint dataset are freely available at https://wustl.box.com/s/7xfbmxq2r4kg8p8bfc7vpqlrmqvhm0lx. Genomic and phenotypic data for the FINRISK cohort are or will soon be obtainable through THL Biobank, the Finnish Institute for Health and Welfare, Finland (https://thl.fi/en/web/thl-biobank).
